Felipe Melo Cruz

12PUBLICATIONS
89CO-AUTHORS
Predictive and prognostic markersOncology and carcinogenesis not elsewhere classifiedCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Respiratory diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Aug 13, 2025
Prognostic factors of meningeal carcinomatosis in breast cancer patients.

Flávia de Oliveira Lima, Renata Tortato Meneguetti, Auro Del Giglio

|Jul 23, 2025
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without <i>BRCA</i> Mutation.

Panagiotis A Konstantinopoulos, Jae Weon Kim, Gilles Freyer

|May 14, 2025
Omission of dexamethasone in prophylaxis for highly emetogenic chemotherapy in patients with breast cancer.

Camilla Vieira de Rebouças, Rafaela de Brito Alves, Alayne Magalhães Trindade Domingues Yamada

|Jun 10, 2024
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study.

Natasha B Leighl, Hiroaki Akamatsu, Sun Min Lim

|Mar 27, 2024
Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study.

Miguel Martín, Elgene Lim, Mariana Chavez-MacGregor

|Dec 21, 2023
Febrile neutropenia incidence and the variable toxicity profile between brand and generic docetaxel in the adjuvant treatment of breast cancer with docetaxel and cyclophosphamide regimen.

Flávia Viécili Tarcha, Ana Luísa de Castro Baccarin, Lilian Arruda do Rêgo Barros

Pageof 2